Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Keratosis, Actinic 5Neoplasms 2Neoplasm Metastasis 2Melanoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Tuberous Sclerosis 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors Harboring NTRK Fusion 1Small Cell Lung Carcinoma 1Seizures 1Prostatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, T-Cell 1Lung Neoplasms 1Leukemia 1Lennox Gastaut Syndrome 1Head and Neck Neoplasms 1Epilepsies, Myoclonic 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Anemia 1Advanced Solid Tumors 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 40Gemcitabine 37Cisplatin 28Carboplatin 17enfortumab vedotin 15Nivolumab 15Mitomycin 14atezolizumab 13avelumab 12Docetaxel 10vinflunine 95-aminolevulinic acid hexyl ester 9apaziquone 8Paclitaxel 8BCG Vaccine 7durvalumab 6Fluorouracil 6Cystectomy 6sacituzumab govitecan 4Surgical Procedures, Operative 4Drug Therapy 4vofatamab 3valrubicin 3tisotumab vedotin 3erdafitinib 3cemiplimab 3belinostat 3Therapeutic Uses 3Ramucirumab 3Cystoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Urinary Bladder Neoplasms × Solutions × Clear all
NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡